117 related articles for article (PubMed ID: 22702968)
1. Leukaemic transformation with romiplostim.
Gardner K; Mathe S; Sahu S
Br J Haematol; 2012 Jul; 158(2):153. PubMed ID: 22702968
[No Abstract] [Full Text] [Related]
2. Romiplostim: leukaemia after myelodysplastic syndromes.
Prescrire Int; 2012 May; 21(127):129. PubMed ID: 22844683
[No Abstract] [Full Text] [Related]
3. Progression of romiplostim myelofibrosis to myeloproliferative neoplasm.
Dadfarnia T; Lee S
Blood; 2014 Mar; 123(13):1987. PubMed ID: 24800303
[No Abstract] [Full Text] [Related]
4. Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy.
Fenaux P; Muus P; Kantarjian H; Lyons RM; Larson RA; Sekeres MA; Becker PS; Orejudos A; Franklin J
Br J Haematol; 2017 Sep; 178(6):906-913. PubMed ID: 28616874
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of thrombopoietin-receptor agonists in myelodysplastic syndromes: a systematic review and meta-analysis of randomized controlled trials.
Prica A; Sholzberg M; Buckstein R
Br J Haematol; 2014 Dec; 167(5):626-38. PubMed ID: 25155450
[TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial.
Kantarjian HM; Fenaux P; Sekeres MA; Szer J; Platzbecker U; Kuendgen A; Gaidano G; Wiktor-Jedrzejczak W; Carpenter N; Mehta B; Franklin J; Giagounidis A
Lancet Haematol; 2018 Mar; 5(3):e117-e126. PubMed ID: 29396092
[TBL] [Abstract][Full Text] [Related]
7. Romiplostim-induced myelofibrosis.
Rashidi A; Roullet MR
Blood; 2013 Sep; 122(12):2001. PubMed ID: 24175353
[No Abstract] [Full Text] [Related]
8. Portal vein thrombosis as complication of romiplostim treatment in a cirrhotic patient with hepatitis C-associated immune thrombocytopenic purpura.
Dultz G; Kronenberger B; Azizi A; Mihm U; Vogl TJ; Sarrazin U; Sarrazin C; Zeuzem S; Hofmann WP
J Hepatol; 2011 Jul; 55(1):229-32. PubMed ID: 21310200
[TBL] [Abstract][Full Text] [Related]
9. Association between acute myelogenous leukemia and thrombopoietin receptor agonists in patients with immune thrombocytopenia.
Oshima Y; Yuji K; Tanimoto T; Hinomura Y; Tojo A
Intern Med; 2013; 52(19):2193-201. PubMed ID: 24088751
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of romiplostim in patients with eltrombopag-resistant or -intolerant immune thrombocytopenia.
Tsukamoto S; Nakaseko C; Takeuchi M; Kumagai K; Komatsu T; Tanaka H; Hara S; Koizumi M; Imai H; Yokota A; Takeuchi M; Inokuchi K; Matsuura Y; Aotsuka N; Wakita H
Br J Haematol; 2013 Oct; 163(2):286-9. PubMed ID: 23862773
[No Abstract] [Full Text] [Related]
11. Romiplostim-induced erythromelalgia in a patient with idiopathic thrombocytopenic purpura.
Kluger N; Bessis D; Quittet P; Rigau V; Guillot B; Girard C
Br J Dermatol; 2009 Aug; 161(2):482-4. PubMed ID: 19486002
[No Abstract] [Full Text] [Related]
12. Extensive cerebral venous sinus thrombosis after romiplostim treatment for immune thrombocytopenia (ITP) despite severe thrombocytopenia.
Ho P; Khan S; Crompton D; Hayes L
Intern Med J; 2015 Jun; 45(6):682-3. PubMed ID: 26059883
[No Abstract] [Full Text] [Related]
13. Romiplostim in chronic immune thrombocytopenic purpura.
Cersosimo RJ
Clin Ther; 2009 Sep; 31(9):1887-907. PubMed ID: 19843480
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of the thrombopoietin receptor agonist romiplostim in patients aged ≥ 65 years with immune thrombocytopenia.
Michel M; Wasser J; Godeau B; Aledort L; Cooper N; Tomiyama Y; Khellaf M; Wang X
Ann Hematol; 2015 Dec; 94(12):1973-80. PubMed ID: 26341755
[TBL] [Abstract][Full Text] [Related]
15. Romiplostim: new drug. Thrombocytopenic purpura: for selected patients, with close monitoring.
Prescrire Int; 2009 Dec; 18(104):246. PubMed ID: 20020571
[No Abstract] [Full Text] [Related]
16. Integrated analysis of long-term safety in patients with chronic immune thrombocytopaenia (ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostim.
Cines DB; Gernsheimer T; Wasser J; Godeau B; Provan D; Lyons R; Altomare I; Wang X; Lopez A
Int J Hematol; 2015 Sep; 102(3):259-70. PubMed ID: 26201709
[TBL] [Abstract][Full Text] [Related]
17. Reversible bone marrow reticulin fibrosis as a side effect of romiplostim therapy for the treatment of chronic refractory immune thrombocytopenia.
Leung T; Lokan J; Turner P; Smith C
Pathology; 2011 Aug; 43(5):520-2. PubMed ID: 21753725
[No Abstract] [Full Text] [Related]
18. Salvage therapy of autoimmune thrombocytopenic purpura revealing non-Hodgkin lymphoma by the thrombopoietin receptor agonist romiplostim.
Al-Nawakil C; Park S; Chapuis N; Dreyfus F; Szwebel TA; Gibault L; Molina T; Hermine O; Bouscary D; Tamburini J
Br J Haematol; 2012 Jan; 156(1):145-7. PubMed ID: 21848881
[No Abstract] [Full Text] [Related]
19. [Development of thrombopoietin receptor agonists].
Miyakawa Y
Rinsho Ketsueki; 2009 Oct; 50(10):1434-43. PubMed ID: 19915352
[No Abstract] [Full Text] [Related]
20. Platelet fluctuations during thrombopoietin-receptor agonist treatment: correlation with platelet apoptosis.
Polverelli N; Catani L; Sollazzo D; Vianelli N; Palandri F
Ann Hematol; 2015 Feb; 94(2):339-41. PubMed ID: 24994539
[No Abstract] [Full Text] [Related]
[Next] [New Search]
